ClinicalTrials.gg

Food Hypersensitivity clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 378 studies for Food Hypersensitivity across more than 10 countries. 90 are recruiting or about to start. 214 of them are mainly about Food Hypersensitivity (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 5 narrower conditions too, such as Peanut Hypersensitivity: 600 studies, 123 open.

Status

Completed
190
Recruiting
52
Status unknown
40
Terminated
28
Not yet recruiting
28
Active, not recruiting
20

Phase

Phase 2
64
Phase 1
35
Phase 3
12
Phase 4
11
Early Phase 1
3

Where

United States
139
France
31
United Kingdom
26
Spain
23
Italy
20
Poland
19

Who develops what

Add Food Hypersensitivity to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 1 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Longbio Pharma (Suzhou), Novartis and UCB here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
remibrutinibApproved: US 2025 · EU 2026☆ Track1 live phase-3 study: NCT07768371Novartis

The 1 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.Palforzia · DBV Technologies · Phase 3 named, not the main aimNCT07003919 Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) — primary endpoint: DBPC Treatment Period: Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs) · 480 enrolled
  • 16 Jul 2027 est.Lisinopril · longbio pharma suzhou · Phase 2 named, not the main aimNCT07816432 A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy — primary endpoint: Proportion of participants who consumed a cumulative dose of 24 g gluten protein without dose limiting symptoms in the food exercise challenge test. · 12 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Food Hypersensitivity studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open

Coming up

36studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 52 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 40 (77%) stop at 75 or younger. 44 (85%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 17 (33%) take healthy volunteers.

Recruiting studies that take each age, of 52
AgeWomenMen
1034 (65%)34 (65%)
1827 (52%)27 (52%)
3024 (46%)24 (46%)
4023 (44%)23 (44%)
5023 (44%)23 (44%)
6518 (35%)18 (35%)
7512 (23%)12 (23%)
8511 (21%)11 (21%)

Across all 378 studies, recruiting or not: 79% stop at 75 or younger and 76% at 65; 78% take children; 2% are for women only and 0% for men only; 30% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Food Hypersensitivity studies take

Of 19 phase 2 interventional studies under Food Hypersensitivity, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 246 mo19–71 · 19 studies——
Interventional, no phase30 mo13–50 · 85 studies—29 mo13–50 · 81 studies
Observational42 mo19–250 · 42 studies—42 mo19–250 · 42 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 378. Browse all 378 → or search them.